JP2016513124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513124A5 JP2016513124A5 JP2015558976A JP2015558976A JP2016513124A5 JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5 JP 2015558976 A JP2015558976 A JP 2015558976A JP 2015558976 A JP2015558976 A JP 2015558976A JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutical composition
- pharmaceutically acceptable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 102000003688 G-protein coupled receptors Human genes 0.000 claims 1
- 108090000045 G-protein coupled receptors Proteins 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229960003957 Dexamethasone Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
Description
実施例２の化合物およびデキサメサゾン(Ｄｅｘ)を独立してまたは組み合わせで、上記自然発症エリテマトーデスのＭＲＬ／ｌｐｒマウスモデルによるアッセイで試験し、結果を表１０に示す。実施例２により例示される本発明の化合物およびデキサメサゾンのいずれも、本試験において、１００mg／dLを超えるタンパク質尿素濃度のマウスの低いパーセンテージにより評価して、疾患進行の阻止を示した。本試験において、実施例２の化合物とデキサメサゾンの組み合わせを投与されたマウスは何れも１００mg／mLを超えるタンパク質尿素濃度を示さなかった。
Claims (12)
- 式(Ｉ)
の化合物および／またはその塩。 - Ｒが−ＯＨである、請求項１に記載の化合物またはその塩。
- Ｒが−ＯＰ(Ｏ)(ＯＨ)２である、請求項１に記載の化合物またはその塩。
- 次の構造
- 次の構造
- 結晶性固体である、請求項５に記載の化合物またはその塩。
- 次の構造
- 次の構造
- 請求項２に記載の化合物またはその薬学的に許容される塩および薬学的に許容される担体を含む、医薬組成物。
- Ｇタンパク質共役受容体Ｓ１Ｐ１の活性と関係する疾患または障害を治療するための、請求項１に記載の化合物またはその薬学的に許容される塩を含む医薬組成物であって、哺乳動物患者に該医薬組成物を投与することを特徴とする、医薬組成物。
- 自己免疫性疾患または慢性炎症性疾患を治療するための、請求項１に記載の化合物またはその薬学的に許容される塩を含む医薬組成物であって、哺乳動物患者に該医薬組成物を投与することを特徴とする、医薬組成物。
- 自己免疫性疾患または慢性炎症性疾患が狼瘡、多発性硬化症、炎症性腸疾患およびリウマチ性関節炎から選択される、請求項１１に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767531P | 2013-02-21 | 2013-02-21 | |
| US61/767,531 | 2013-02-21 | ||
| PCT/US2014/017534 WO2014130752A2 (en) | 2013-02-21 | 2014-02-21 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513124A JP2016513124A (ja) | 2016-05-12 |
| JP2016513124A5 true JP2016513124A5 (ja) | 2017-03-16 |
| JP6277210B2 JP6277210B2 (ja) | 2018-02-07 |
Family
ID=50272738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558976A Active JP6277210B2 (ja) | 2013-02-21 | 2014-02-21 | 二環式化合物 |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US9115054B2 (ja) |
| EP (1) | EP2958888B1 (ja) |
| JP (1) | JP6277210B2 (ja) |
| KR (1) | KR102242265B1 (ja) |
| CN (1) | CN105026362B (ja) |
| AR (1) | AR094851A1 (ja) |
| AU (1) | AU2014218883B2 (ja) |
| BR (1) | BR112015019919A2 (ja) |
| CA (1) | CA2902168C (ja) |
| CL (1) | CL2015002358A1 (ja) |
| CY (1) | CY1118641T1 (ja) |
| DK (1) | DK2958888T3 (ja) |
| EA (1) | EA025294B1 (ja) |
| ES (1) | ES2613262T3 (ja) |
| HK (1) | HK1218111A1 (ja) |
| HR (1) | HRP20170247T1 (ja) |
| HU (1) | HUE031626T2 (ja) |
| IL (1) | IL240613B (ja) |
| LT (1) | LT2958888T (ja) |
| MA (1) | MA38425B1 (ja) |
| MX (1) | MX2015010347A (ja) |
| MY (1) | MY173990A (ja) |
| PE (1) | PE20151746A1 (ja) |
| PH (1) | PH12015501793B1 (ja) |
| PL (1) | PL2958888T3 (ja) |
| PT (1) | PT2958888T (ja) |
| RS (1) | RS55703B1 (ja) |
| SG (1) | SG11201506408TA (ja) |
| SI (1) | SI2958888T1 (ja) |
| SM (1) | SMT201700115B (ja) |
| TN (1) | TN2015000356A1 (ja) |
| TW (1) | TWI613182B (ja) |
| UY (1) | UY35338A (ja) |
| WO (1) | WO2014130752A2 (ja) |
| ZA (1) | ZA201506965B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015009731A2 (en) | 2013-07-15 | 2015-01-22 | The Regents Of The University Of California | Azacyclic constrained analogs of fty720 |
| UY36274A (es) | 2014-08-20 | 2016-02-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g |
| CA2999177A1 (en) * | 2015-09-24 | 2017-03-30 | The Regents Of The University Of California | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment |
| WO2018045149A1 (en) | 2016-09-02 | 2018-03-08 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| WO2019032631A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | OXIME ETHER COMPOUNDS |
| WO2021062168A1 (en) * | 2019-09-25 | 2021-04-01 | The Regents Of The University Of California | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| EP1575964B1 (en) | 2002-01-18 | 2009-11-11 | Merck & Co., Inc. | N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
| US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| MXPA05012461A (es) | 2003-05-19 | 2006-02-22 | Irm Llc | Compuestos y composiciones inmunosupresores. |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| JP2008530135A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト |
| BRPI0607156A2 (pt) | 2005-02-18 | 2009-08-11 | Innodia Inc | composto, composição farmacêutica, uso do composto, kit farmacêutico, método para estimular a absorção de glicose por células de músculo e/ou célula de adipócito e método para estimular a secreção pancreática |
| US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| MX2007011672A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
| CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
| US20080306124A1 (en) | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| AU2007205114B2 (en) | 2006-01-06 | 2012-11-08 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| AU2007209961A1 (en) | 2006-01-27 | 2007-08-09 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| AU2007229850A1 (en) | 2006-03-23 | 2007-10-04 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| CA2648303C (en) | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| AU2007292992B2 (en) | 2006-09-08 | 2013-01-10 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| MX2009006751A (es) * | 2006-12-21 | 2009-06-30 | Abbott Lab | Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato. |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| BRPI0806940A2 (pt) | 2007-02-02 | 2014-05-06 | Hoffmann La Roche | 2-amino-oxazolinas como ligantes taar1 para distúrbios do snc |
| MX2009009597A (es) | 2007-03-16 | 2009-09-16 | Actelion Pharmaceuticals Ltd | Derivados de amino-piridina como agonistas del receptor s1p1/edg1. |
| US8202865B2 (en) | 2007-10-04 | 2012-06-19 | Merck Serono Sa | Oxadiazole derivatives |
| BRPI0818804A2 (pt) | 2007-11-01 | 2015-04-22 | Actelion Pharmaceuticals Ltd | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| EP2344446A4 (en) | 2008-10-17 | 2012-04-04 | Akaal Pharma Pty Ltd | S1P RECEPTOR MODULATORS |
| BRPI0923178A2 (pt) | 2008-12-18 | 2016-02-16 | Merck Serono Sa | derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| CN102361868A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 作为1-磷酸-鞘氨醇激动剂的吡唑-1，2，4-噁二唑衍生物 |
| CN102361867A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| EP2395986A1 (en) | 2009-02-10 | 2011-12-21 | Abbott Laboratories | Methods for preparing s1p receptor agonists and antagonists |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2493866A1 (en) | 2009-10-29 | 2012-09-05 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| CN103119038B (zh) | 2010-04-23 | 2016-05-04 | 百时美施贵宝公司 | 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN102260178A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| ES2539256T3 (es) | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| US8629282B2 (en) | 2010-11-03 | 2014-01-14 | Bristol-Myers Squibb Company | Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases |
| EP2685971A2 (en) | 2011-03-18 | 2014-01-22 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| JP5090580B1 (ja) | 2011-04-26 | 2012-12-05 | パナソニック株式会社 | 暖房システム及び暖房システム制御方法 |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| TWI631097B (zh) | 2012-07-27 | 2018-08-01 | 百健Ｍａ公司 | 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物 |
-
2014
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en active Application Filing
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh active Active
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko active IP Right Grant
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja active Active
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
-
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793B1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
-
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
- 2016-05-27 HK HK16106055.1A patent/HK1218111A1/zh not_active IP Right Cessation
-
2017
- 2017-02-16 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513124A5 (ja) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2016528301A5 (ja) | ||
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| JP2010174019A5 (ja) | ||
| RU2019121667A (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| JP2019516739A5 (ja) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2016510326A5 (ja) | ||
| JP2013518036A5 (ja) | ||
| JP2017511377A5 (ja) | ||
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| JP2014148552A5 (ja) | ||
| JP2019052094A5 (ja) | ||
| BR112012022632A2 (pt) | Medicamento compreendendo agonista de ep4 | |
| EA201990668A1 (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2019515033A5 (ja) | ||
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 |